Payment overview · 2025
General Payments
$461.16
32 reported records · 11 companies
Healthcare provider profile · identity verified
Barton David Parish, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · HOT SPRINGS, AR · NPI 1013922988
Verified facts
What the public records show
CMS Open Payments records show Barton David Parish, M.D. received $461.16 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.07 | 31.7% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.52 | 10.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.12 | 10.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.18 | 10.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.49 | 8.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.17 | 7.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.62 | 6.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.16 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.13 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.89 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.81 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $461.16 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.49 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.58 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.12 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.18 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.62 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 50 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 406 | 122 |
| Lisinopril | Lisinopril | 304 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 284 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 57 |
| Tramadol Hcl | Tramadol Hcl | 198 | 48 |
| Metformin Hcl | Metformin Hcl | 178 | 53 |
| Clonazepam | Clonazepam | 172 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 42 |
| Losartan Potassium | Losartan Potassium | 145 | 45 |
| Gabapentin | Gabapentin | 144 | 35 |
| Omeprazole | Omeprazole | 135 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 111 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 15 |
| Sertraline Hcl | Sertraline Hcl | 106 | 33 |
| Simvastatin | Simvastatin | 105 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 104 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 38 |
| Potassium Chloride | Potassium Chloride | 98 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 25 |
| Famotidine | Famotidine | 91 | 26 |
| Glipizide | Glipizide | 89 | 23 |
| Trazodone Hcl | Trazodone Hcl | 86 | 28 |
| Azithromycin | Azithromycin | 78 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 27 |
| Temazepam | Temazepam | 68 | suppressed |
| Allopurinol | Allopurinol | 65 | 17 |
| Buspirone Hcl | Buspirone Hcl | 64 | 13 |
| Baclofen | Baclofen | 62 | 26 |
| Ezetimibe | Ezetimibe | 61 | 15 |
| Pregabalin | Pregabalin | 61 | 18 |
| Lorazepam | Lorazepam | 56 | 13 |
| Methylprednisolone | Methylprednisolone | 55 | 44 |
| Ozempic | Semaglutide | 55 | suppressed |
| Carvedilol | Carvedilol | 53 | 13 |
| Bupropion Xl | Bupropion Hcl | 52 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Eliquis | Apixaban | 50 | 12 |
| Clonidine Hcl | Clonidine Hcl | 48 | 17 |
| Irbesartan | Irbesartan | 48 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 15 |
| Meloxicam | Meloxicam | 46 | 18 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Furosemide | Furosemide | 45 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 19 |
| Alendronate Sodium | Alendronate Sodium | 38 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 11 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 12 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Atenolol | Atenolol | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $461.16 · 32 records | ABBVIE INC. | CARDIOMEMS, ELIQUIS, FARXIGA, GEMTESA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error